Bang & Olufsen A/S
Bang & Olufsen A/S - Transactions in connection with share buyback programme to hedge the company’s share-based incentive programmes
Bang & Olufsen A/S - Transactions in connection with share buyback programme to hedge the company’s share-based incentive programmes
On 15 August 2025, Bang & Olufsen initiated a share buyback programme with the purpose of hedging the company’s share-based long-term incentive programmes in accordance with EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”).
Under the share buyback programme, which runs from 15 August 2025 and will end no later than 14 August 2026, Bang & Olufsen intends to buy back shares for an amount of up to DKK 65 million.
The following transactions have been made under the program in the period 17 to 21 November 2025.
| No. of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| Total previous announcement | 1,826,676 | 13.72 | 25,062,606.08 |
| 17 November 2025 | 35,000 | 13.64 | 477,344.00 |
| 18 November 2025 | 35,000 | 13.30 | 465,447.50 |
| 19 November 2025 | 35,000 | 13.22 | 462,546.00 |
| 20 November 2025 | 35,000 | 13.25 | 463,879.50 |
| 21 November 2025 | 30,087 | 13.20 | 397,238.66 |
| Total this period | 170,087 | 13.33 | 2,266,455.66 |
| Accumulated under the programme | 1,996,763 | 13.69 | 27,329,061.74 |
Following the above transactions, Bang & Olufsen holds a total of 4,181,499 own shares corresponding to 2.84% of the total share capital and the total voting rights in the company.
Details of each transaction are included as appendix.
For further information, please contact: Sr. Director, Strategy & Investor Relations, Cristina Rønde Hefting, phone: +45 4153 7303.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Pandora A/S24.11.2025 12:42:26 CET | Press release
Transactions in connection with share buyback programme
Novo Nordisk A/S24.11.2025 12:20:53 CET | Press release
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
Netcompany Group A/S24.11.2025 11:55:57 CET | Press release
Transactions in connection with share buyback programme
Djurslands Bank A/S24.11.2025 11:41:25 CET | Pressemeddelelse
Aktietilbagekøb i Djurslands Bank – transaktioner i uge 47
Alvotech24.11.2025 11:30:00 CET | Press release
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom